• Product name

    Anti-LRRK2 antibody [MJFF5 (68-7)]
    See all LRRK2 primary antibodies
  • Description

    Rabbit monoclonal [MJFF5 (68-7)] to LRRK2
  • Host species

  • Tested applications

    Suitable for: IP, WBmore details
  • Species reactivity

    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human LRRK2 aa 950 to the C-terminus. The exact sequence is proprietary.
    Database link: Q5S007

  • Positive control

    • Human brain cortex and mouse brain cortex lysates.
  • General notes

    Well-characterized antibodies to efficiently detect and purify LRRK2 protein are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research, The Michael J. Fox Foundation (MJFF), working with Epitomics, Inc., has generated unique and high quality LRRK2 rabbit monoclonal antibodies to be widely available for PD research community.

    LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase belonging to the ROCO family, which is defined by the presence of a ROC (Ras/GTPase of complex proteins) domain and COR (C-terminal of Roc) region. LRRK2 exhibits kinase activity whereby it can undergo autophosphorylation and can phosphorylate generic substrates. In addition, the GTPase domain of LRRK2 can mediate GDP (guanosine-5′-diphosphate)/GTP (guanosine-5′-triphosphate) binding as well as GTP hydrolysis.

    LRRK2 is mutated in a significant number of Parkinson's disease (PD) patients. Mutations in this gene account for 4% of PD, and are observed in 1% of sporadic PD patients. Clinical symptoms of patients carrying PD-associated mutations of LRRK2 are indistinguishable from typical sporadic PD. The spectra of neuropathological features of PARK8 (type 8), the type corresponding to LRRK2, is broad and appears to encompass those associated with other familial PD cases such as PARK1 (alpha-synuclein) and PARK2 (Parkin). Patients with this gene mutation have typical relatively late onset Parkinsonism with features comparable with idiopathic PD; symptoms include asymmetric rest tremor, bradykinesia, rigidity, and a good response to 3,4-dihyroxy-l-phenylalanine (l-DOPA). The pathology of cases with LRRK2 mutations is pleomorphic.

    This antibody clone (c68-7) has been re-introduced to the Epitomics catalog as characterization efforts have indicated that it performs very well at immunoprecipitating LRRK2 protein from cell lines and tissue lysate. This may facilitate investigators’ ability to more broadly examine alterations in LRRK2 protein levels and activity to interrogate changes in the biological samples.

    For more characterization data and protocols using this LRRK2 Antibody, please refer to Davies, et al. 2013. Biochemical J 453(1):101-113 [PMID: 23560750]

    Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.


  • Form

  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer

    pH: 7.20
    Preservative: 0.01% Sodium azide
    Constituent: 99% PBS
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

  • Clone number

    MJFF5 (68-7)
  • Isotype

  • Research areas


Our Abpromise guarantee covers the use of ab181386 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration. PubMed: 26365310
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 286 kDa.

We recommend customers use 3% milk as the blocking agent for ab181386.


  • Function

    Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease.
  • Tissue specificity

    Expressed in the brain. Expressed in pyramidal neurons in all cortical laminae of the visual cortex, in neurons of the substantia nigra pars compacta and caudate putamen (at protein level). Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
  • Involvement in disease

    Parkinson disease 8
  • Sequence similarities

    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
    Contains 12 LRR (leucine-rich) repeats.
    Contains 1 protein kinase domain.
    Contains 1 Roc domain.
    Contains 7 WD repeats.
  • Domain

    The seven-bladed WD repeat region is critical for synaptic vesicle trafficking and mediates interaction with multiple vesicle-associated presynaptic proteins.
    The Roc domain mediates homodimerization and regulates kinase activity.
  • Post-translational

  • Cellular localization

    Membrane. Cytoplasm. Perikaryon. Mitochondrion. Golgi apparatus. Cell projection, axon. Cell projection, dendrite. Endoplasmic reticulum. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Endosome. Lysosome. Mitochondrion outer membrane. Mitochondrion inner membrane. Mitochondrion matrix. Predominantly associated with intracytoplasmic vesicular and membranous structures (By similarity). Localized in the cytoplasm and associated with cellular membrane structures. Predominantly associated with the mitochondrial outer membrane of the mitochondria. Colocalized with RAB29 along tubular structures emerging from Golgi apparatus. Localizes in intracytoplasmic punctate structures of neuronal perikarya and dendritic and axonal processes.
  • Information by UniProt
  • Database links

  • Alternative names

    • augmented in rheumatoid arthritis 17 antibody
    • AURA17 antibody
    • Dardarin antibody
    • Leucine rich repeat kinase 2 antibody
    • leucine rich repeat serine threonine protein kinase 2 antibody
    • Leucine-rich repeat serine/threonine-protein kinase 2 antibody
    • LRRK 2 antibody
    • LRRK2 antibody
    • LRRK2_HUMAN antibody
    • PARK 8 antibody
    • PARK8 antibody
    • RIPK7 antibody
    • ROCO 2 antibody
    • ROCO2 antibody
    see all


  • Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: LRRK2 knockout HAP1 cell lysate (20 µg) 
    Lane 3: MEF cell lysate (20 µg)
    Lane 4: LRRK2 knockout MEF cell lysate (20 µg) 
    Lane 5: A549 cell lysate (20ug)
    Lane 6: LRRK2 knockout A549 cell lysate (20 µg) 

    Lanes 1 - 6: Merged signal (red and green). Green - ab181386 observed at 238 kDa. Red - loading control, ab18058, observed at 124 kDa.

    ab181386 was shown to specifically react with wildtype HAP1, MEF and A549 cell lysates with additional cross-reactive bands. No bands were observed when LRRK2 knockout samples were used. Wild-type and LRRK2 knockout samples were subjected to SDS-PAGE. Membranes were blocked in 3% milk for 1 hour at room temperature. ab181386 and ab130007 (loading control to Vinculin) were diluted at 2.5 ug/mL and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    Wild-type and LRRK2 knockout MEF and A549 cells were provide as a generous gift from Professor Dario Alessi, MRC Protein Phosphorylation and Ubiquitination Unit (University of Dundee).

  • All lanes : Anti-LRRK2 antibody [MJFF5 (68-7)] (ab181386) at 1 µg/ml

    Lanes 1-2 : Human brain cortex lysate
    Lane 3 : mouse brain cortex lysate
    Lane 4 : LRRK2-knock-out mouse brain cortex lysate

    Developed using the ECL technique.

    Predicted band size: 286 kDa


This product has been referenced in:

  • Bliederhaeuser C  et al. LRRK2 contributes to monocyte dysregulation in Parkinson's disease. Acta Neuropathol Commun 4:123 (2016). Human . Read more (PubMed: 27884177) »
  • Choi I  et al. LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun 6:8255 (2015). IP ; Mouse . Read more (PubMed: 26365310) »
See all 3 Publications for this product

Customer reviews and Q&As

Flow Cytometry
Human Cell (Peripheral Blood (Monocytes))
Yes - ‘Two-step protocol for intracellular (cytoplasmic) proteins’ from eBioscience
Gating Strategy
CD16+/- and CD14++/dim monocytes
Peripheral Blood (Monocytes)
Cell harvesting/tissue preparation method: Peripheral venous blood was collected with a Monovette™ blood drawing system (Sarstedt) and processed within 3 hours post collection. Li-Heparin was used as anticoagulant. Red-blood cells (RBC) were lysed, two times washed in PBS + 10 % FCS, and the remaining leukocytes were blocked with Fc-block (1:20, BioLegend 20 min). Cell surface staining was performed with anti-human antibodies against CD14 and CD16. For intracellular LRRK2 staining the ‘Two-step protocol for intracellular (cytoplasmic) proteins’ from eBioscience was followed.
Sample buffer: PBS + 10%FCS, Permeabilisation Buffer (eBioscience)
IC Fixaction Buffer (eBioscience)

Abcam user community

Verified customer

Submitted Dec 22 2016

For licensing inquiries, please contact partnerships@abcam.com

Sign up